Triclosan: Release from transdermal adhesive formulations and in vitro permeation across human epidermal membranes

International Journal of Pharmaceutics

Volumn 235, Issue 1-2, 2002, Pages 229-236

  Chedgzoy, Paula ^a   Winckle, Gareth ^a   Heard, Charles M ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Malaria; Skin; Trandermal delivery; Transdermal adhesive; Triclosan

Indexed keywords

ANTIMALARIAL AGENT; DUROTAK 2051; DUROTAK 2287; DUROTAK 2516; POLYACRYLIC ACID; TRICLOSAN; UNCLASSIFIED DRUG;

ADHESION; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIPOPHILICITY; PRIORITY JOURNAL; SKIN PERMEABILITY; STEADY STATE; TRANSDERMAL PATCH;

ADHESIVES; ADMINISTRATION, CUTANEOUS; ADULT; ANTI-INFECTIVE AGENTS, LOCAL; CHEMISTRY, PHARMACEUTICAL; EPIDERMIS; FEMALE; HUMANS; PERMEABILITY; TRICLOSAN;

EID: 0037139369     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(01)00992-9     Document Type: Article

References (13)

1. Development of controlled transdermal drug delivery using molecular imprinted polymers
2. Triclosan: Applications and safety
3. New agents to combat malaria
4. Selection of drug candidates for transdermal delivery
5. Characterisation of Pseudomonas aeruginosa enoyl-acyl carrier protein reductase (FabI): A target for antimicrobial triclosan and its role in acylated homoserine lactone synthesis
6. Percutaneous penetration and dermal metabolism of triclosan (2,4,4′-Trichloro-2′-hydroxyphenyl ether)
7. In vitro dermal and transdermal delivery of doxycycline from ethanol/Migliol 840
8. A new bacteriostat for skin care products
9. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum